Neural Mechanisms and Clinical Applications of DBS for Modulating Sleep Dysregulation in PD

Launched by XUANWU HOSPITAL, BEIJING · Mar 30, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how a treatment called deep brain stimulation (DBS) can help improve sleep problems in people with Parkinson's disease (PD). While DBS is known to help with the movement issues caused by PD, many patients also struggle with sleep disorders that can greatly affect their quality of life. The researchers want to understand how DBS impacts sleep patterns and brain activity during sleep. They will use a special device that monitors sleep and brain signals to see how DBS affects sleep stages and overall sleep quality.

To participate in this trial, you need to have a diagnosis of Parkinson's disease and have already received the DBS treatment. You're also expected to be able to cooperate with follow-up evaluations. During the study, participants will have their sleep monitored while the DBS is turned on and off, helping researchers find the best way to improve sleep. This research aims to develop new strategies for better managing sleep issues in Parkinson's patients, which could lead to improved overall well-being.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Diagnosis of Parkinson's disease: The diagnostic criteria for Parkinson's disease are the Clinical Diagnostic Criteria of UK PD Society Brain Bank Clinical Diagnostic Criteria or 2015 MDS Clinical Diagnostic Criteria for PD.All diagnoses of Parkinson's disease were made by three neurologists who were experienced in the field of movement disorders.
• • 2. Patients who underwent bilateral STN-DBS(Medtronic Percept™ PC)
• • 3. Patients who can cooperate with the completion of postoperative follow-up and clinical evaluation.
• Exclusion Criteria:
• • 1. Patients who underwent other brain surgery;
• • 2. Other patients with secondary Parkinson's syndrome and Parkinsonism-plus syndrome;
• • 3. Patients with other central nervous system and peripheral nervous system diseases;
• • 4. Patients complicated with severe medical system diseases, or unable to tolerate clinical evaluation;
• • 5. Patients with severe mental illness;
• • 6. Patients who cannot complete informed consent due to cognitive and communication barriers, or refuse to sign informed consent.